Results of a tailored multimodal lifestyle follow-up care program focusing on physical activity, nutritional behavior and psychological processes in adolescent and young adult cancer survivors: The ...
*Safety data percentages are calculated from the safety population (n=338 for durvalumab + GemCis and n=342 for placebo + GemCis). This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal ...
Efforts to reduce global cancer disparities begin with an understanding of geographic patterns in cancer incidence, mortality, and prevalence. Using the GLOBOCAN (2002) and Cancer Incidence in Five ...
The decision to treat a patient with stage II colon cancer with adjuvant chemotherapy can be challenging. Although the benefit of treatment is clear in most patients with stage III disease, the ...
Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304. An international, multicenter, prospective randomized trial ...
Radiation oncology has undergone a profound transformation over the past 50 years, evolving from broad techniques to highly conformal, precision-guided treatments. This review synthesizes key ...
Improving detection of higher-risk or locally advanced disease features in stage I and II renal cell carcinoma. This is an ASCO Meeting Abstract from the 2020 Genitourinary Cancers Symposium. This ...
Biological characteristics and prognostic value of Tfh-like cells in the tumor tissue of breast cancer. This is an ASCO Meeting Abstract from the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.
This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not include a full text component.
Methodologic Considerations in Assessing Invasive Disease-Free Survival as a Surrogate End Point for Overall Survival in Trials for Early Breast Cancer The following represents disclosure information ...
Immune Checkpoint Combos in Metastatic Castration-Resistant Prostate Cancer: Where Are We Going, What Are We Doing, and Why? The following represents disclosure information provided by the author of ...
SRC-homology 2 domain-containing phosphatase 2 (SHP2) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma (LUAD).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results